{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:38:51Z","timestamp":1787585931248,"version":"build-2736575974"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"Supplement_L","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Heart Failure Association of the European Society of Cardiology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cachexia is a multifactorial disease characterized by a pathologic shift of metabolism towards a more catabolic state. It frequently occurs in patients with chronic diseases such as chronic heart failure and is especially common in the elderly. In patients at risk, cardiac cachexia is found in about 10% of heart failure patients. The negative impact of cardiac cachexia on mortality, morbidity, and quality of life demonstrates the urgent need to find new effective therapies against cardiac cachexia. Furthermore, exercise training and nutritional support can help patients with cardiac cachexia. Despite ongoing efforts to find new therapies for cachexia treatment, also new preventive strategies are needed.<\/jats:p>","DOI":"10.1093\/eurheartj\/suz241","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T08:08:18Z","timestamp":1577088498000},"page":"L24-L27","source":"Crossref","is-referenced-by-count":43,"title":["Cardiac cachexia"],"prefix":"10.1093","volume":"21","author":[{"given":"Alessia","family":"Lena","sequence":"first","affiliation":[{"name":"Division of Cardiology and Metabolism, Department of Cardiology, Charit\u00e9\u2014Campus Virchow Klinikum (CVK), Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Department of Cardiology, Charit\u00e9\u2014Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203 Berlin, Germany"},{"name":"Berlin Institute of Health Center for Regenerative Therapies (BCRT), F\u00f6hrer Str. 15, 13353 Berlin, Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Hessische Strasse 3-4, 10115 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ebner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Goettingen, Robert-Koch-Stra\u00dfe 40, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S","family":"Anker","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Metabolism, Department of Cardiology, Charit\u00e9\u2014Campus Virchow Klinikum (CVK), Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Department of Cardiology, Charit\u00e9\u2014Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203 Berlin, Germany"},{"name":"Berlin Institute of Health Center for Regenerative Therapies (BCRT), F\u00f6hrer Str. 15, 13353 Berlin, Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Hessische Strasse 3-4, 10115 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"2019122303073854800_suz241-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2019122303073854800_suz241-B2","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/ejhf.1098","article-title":"Co-morbidities in heart failure beginning to sprout-and no end in sight?","volume":"19","author":"von Haehling","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ehf2.12330","article-title":"Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial","volume":"5","author":"Kleiner Shochat","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ehf2.12125","article-title":"Palliative care in heart failure: facts and numbers","volume":"4","author":"Riley","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ehf2.12156","article-title":"Gender-adjusted and age-adjusted economic inpatient burden of congestive heart failure: cost and disability-adjusted life-year analysis","volume":"4","author":"Salem","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo\u2010Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/ehf2.12338","article-title":"Sacubitril\u2013valsartan in heart failure and multimorbidity patients","volume":"5","author":"Fraile","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ejhf.769","article-title":"Impact of QRS complex duration and morphology on left ventricular reverse remodelling and left ventricular function improvement after cardiac resynchronization therapy","volume":"19","author":"van der Bijl","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ejhf.779","article-title":"Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B10","first-page":"16","article-title":"Medical treatment of heart failure with reduced ejection fraction\u2014prognostic indication","volume":"10","author":"Rosano","year":"2017","journal-title":"Int Cardiovasc Forum J"},{"key":"2019122303073854800_suz241-B11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ejhf.901","article-title":"Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality","volume":"20","author":"Platz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ehf2.12239","article-title":"Outcomes following heart failure hospitalizations in a regional Australian setting between 2005 and 2014","volume":"5","author":"Al-Omary","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/ejhf.812","article-title":"High prevalence of sub-clinical cerebral infarctions in patients with heart failure with preserved ejection fraction","volume":"19","author":"Cogswell","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int J Cardiol"},{"key":"2019122303073854800_suz241-B15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.746","article-title":"Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure","volume":"19","author":"Sokolski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17987\/icfj.v13i0.550","article-title":"Detection of early heart failure with preserved ejection fraction (HFpEF) in metabolic syndrome patients detected as part of a national screening programme in middle aged subjects","volume":"13","author":"\u010celutkien\u0117","year":"2018","journal-title":"Int Cardiovasc Forum J"},{"key":"2019122303073854800_suz241-B17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.15420\/cfr.2018.22.2","article-title":"Frailty in heart failure: implications for management","volume":"4","author":"Vitale","year":"2018","journal-title":"Card Fail Rev"},{"key":"2019122303073854800_suz241-B18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ehf2.12389","article-title":"Metabolic disorders in heart failure and cancer","volume":"5","author":"Lena","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ehf2.12387","article-title":"Skeletal muscle wasting in chronic heart failure","volume":"5","author":"Suzuki","year":"2018","journal-title":"ESC Heart Failure"},{"key":"2019122303073854800_suz241-B20","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/ejhf.1314","article-title":"Muscling up to improve heart failure prognosis","volume":"20","author":"Ventura","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ehf2.12209","article-title":"Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"4","author":"Saitoh","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ejhf.1304","article-title":"Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"20","author":"Emami","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ehf2.12388","article-title":"Muscle wasting and sarcopenia in heart failure: a brief overview of the current literature","volume":"5","author":"Haehling","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/jcsm.12388","article-title":"Cachexia as a common characteristic in multiple chronic disease","volume":"9","author":"Scherbakov","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"2019122303073854800_suz241-B26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcsm.12167","article-title":"Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016","volume":"7","author":"von Haehling","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation\u2014cause or consequence of heart failure or both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"2019122303073854800_suz241-B28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.921","article-title":"The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology","volume":"19","author":"van Bilsen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ehf2.12223","article-title":"Autonomic dysfunction is associated with cardiac remodelling in heart failure patients","volume":"5","author":"Ali","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinbiochem.2013.10.025","article-title":"Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia","volume":"47","author":"Martins","year":"2014","journal-title":"Clin Biochem"},{"key":"2019122303073854800_suz241-B31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/ejhf.942","article-title":"Immune mechanisms in heart failure","volume":"19","author":"Zhang","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2019122303073854800_suz241-B32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ehf2.12237","article-title":"Muscle wasting and sarcopenia in heart failure and beyond: update 2017","volume":"4","author":"Springer","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jcsm.12193","article-title":"Muscle wasting in young patients with dilated cardiomyopathy","volume":"8","author":"Hajahmadi","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B34","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019122303073854800_suz241-B35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.5114\/aoms.2018.76279","article-title":"Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview","volume":"14","author":"Michalska-Kasiczak","year":"2018","journal-title":"Arch Med Sci"},{"key":"2019122303073854800_suz241-B36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ehf2.12184","article-title":"Cardiac muscle wasting in individuals with cancer cachexia","volume":"4","author":"Barkhudaryan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.15420\/cfr.2017:3:2","article-title":"Cardiac atrophy and heart failure in cancer","volume":"3","author":"Sweeney","year":"2017","journal-title":"Card Fail Rev"},{"key":"2019122303073854800_suz241-B38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ehf2.12356","article-title":"Do we need a reference standard for the muscle mass measurements?","volume":"5","author":"Scherbakov","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019122303073854800_suz241-B39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jcsm.12308","article-title":"Dual energy X-ray absorptiometry: gold standard for muscle mass?","volume":"9","author":"Scafoglieri","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jcsm.12268","article-title":"Pitfalls in the measurement of muscle mass: a need for a reference standard","volume":"9","author":"Buckinx","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MED.0000000000000360","article-title":"Current body composition measurement techniques","volume":"24","author":"Lemos","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2019122303073854800_suz241-B42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.ejrad.2016.03.001","article-title":"Muscle analysis using pQCT, DXA and MRI","volume":"85","author":"Erlandson","year":"2016","journal-title":"Eur J Radiol"},{"key":"2019122303073854800_suz241-B43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcsm.12159","article-title":"Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating?","volume":"8","author":"Gonzalez","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.nut.2011.11.024","article-title":"Cachexia assessed by bioimpedance vector analysis as a prognostic indicator in chronic stable heart failure patients","volume":"28","author":"Castillo-Mart\u00ednez","year":"2012","journal-title":"Nutrition"},{"key":"2019122303073854800_suz241-B45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jcsm.12172","article-title":"Panoramic ultrasound: a novel and valid tool for monitoring change in muscle mass","volume":"8","author":"Scott","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcsm.12278","article-title":"Dilution of oral D3-creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm","volume":"9","author":"Shankaran","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/japplphysiol.00455.2016","article-title":"Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA","volume":"124","author":"Clark","year":"2018","journal-title":"J Appl Physiol"},{"key":"2019122303073854800_suz241-B48","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ijcard.2015.10.033","article-title":"Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment","volume":"202","author":"Drescher","year":"2016","journal-title":"Int J Cardiol"},{"key":"2019122303073854800_suz241-B49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijcard.2017.03.153","article-title":"Myostatin signaling is up-regulated in female patients with advanced heart failure","volume":"238","author":"Ishida","year":"2017","journal-title":"Int J Cardiol"},{"key":"2019122303073854800_suz241-B50","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0735-1097(15)60990-1","article-title":"Serial measurement of tumor necrosis factor-\u03b1, interleukin-6 and vascular endothelial growth factor as a function of cachexia in patients with chronic heart failure: results from the probnp outpatient tailored chronic heart failure (protect) study","volume":"65","author":"Belcher","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2019122303073854800_suz241-B51","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/hc4201.097836","article-title":"Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic\/catabolic factors","volume":"104","author":"Nagaya","year":"2001","journal-title":"Circulation"},{"key":"2019122303073854800_suz241-B52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/eje.0.1450727","article-title":"Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia","volume":"145","author":"Doehner","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2019122303073854800_suz241-B53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.numecd.2013.04.015","article-title":"Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis","volume":"24","author":"Szab\u00f3","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2019122303073854800_suz241-B54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1741826711402735","article-title":"Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure","volume":"19","author":"Lenk","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2019122303073854800_suz241-B55","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/jcsm.12256","article-title":"Casting the net broader to confirm our imaginations: the long road to treating wasting disorders","volume":"8","author":"Haehling","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B56","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/jcsm.12254","article-title":"Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure","volume":"8","author":"Barazzoni","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"2019122303073854800_suz241-B58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib \u00b1 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"2019122303073854800_suz241-B59","doi-asserted-by":"crossref","first-page":"E469","DOI":"10.1152\/ajpendo.00204.2014","article-title":"Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx\/atrogin-1","volume":"307","author":"Bodine","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2019122303073854800_suz241-B60","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/jcsm.12233","article-title":"Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia","volume":"8","author":"Bowen","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B61","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","article-title":"Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study","volume":"361","author":"Anker","year":"2003","journal-title":"Lancet"},{"key":"2019122303073854800_suz241-B62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jcsm.12191","article-title":"Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial","volume":"8","author":"Clark","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jcsm.12189","article-title":"Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis","volume":"8","author":"Tournadre","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B64","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/jcsm.12226","article-title":"The mitochondrial metabolic reprogramming agent trimetazidine as an \u2018exercise mimetic\u2019 in cachectic C26-bearing mice","volume":"8","author":"Molinari","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jcsm.12265","article-title":"Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle","volume":"9","author":"Hulmi","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2019122303073854800_suz241-B66","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jcsm.12321","article-title":"Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease","volume":"9","author":"Sun","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_L\/L24\/31578200\/suz241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_L\/L24\/31578200\/suz241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:12:15Z","timestamp":1695546735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_L\/L24\/5682518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":66,"journal-issue":{"issue":"Supplement_L","published-online":{"date-parts":[[2019,12,23]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suz241","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}